

19 March 2024

Despatch of Renounceable Pro Rata Entitlement Offer Prospectus

Singapore-founded regenerative medicine company **Osteopore Limited (ASX:OSX or the Company)** – a global leader in 3D-printed biomimetic and bioresorbable implants – is pleased to confirm that in accordance with the indicative timetable, the Entitlement Offer Prospectus has been despatched today. Tuesday 19 March 2024 to eligible shareholders.

The Company is seeking to raise approximately A\$3,000,000 (before costs) via a 10-for-1 Renounceable Pro-Rata Entitlement Offer at A\$0.029 per share with shareholders to receive one free-attaching option at an exercise price of A\$0.0387, which will expire two years from the closing date of the Entitlement Offer, for every 5 new shares subscribed under the Entitlement Offer (**Entitlement Offer**). Further details of the Entitlement Offer are set out in the prospectus lodged by the Company with ASIC on 13 March 2024 (**Prospectus**).

Eligible Shareholders are advised that the Entitlement Offer under the Prospectus is now open for subscription. Eligible Shareholders can access their personalised Entitlement and Acceptance forms online at <https://investor.automic.com.au>.

The Entitlement Offer closes at 5:00pm (WST) on Tuesday 2 April 2024.

Indicative Timetable

The Entitlement Offer – as defined in the Prospectus – will be undertaken in accordance with the indicative timetable below:



Event	Date
Prospectus Lodgement Date	13 March 2024
Announcement of Prospectus & Appendix 3B with ASX	13 March 2024
“Ex” date	15 March 2024
Rights start trading	15 March 2024
Record Date to determine Entitlements	18 March 2024
Prospectus with Application Form dispatched	19 March 2024
Entitlement Offer opens for receipt of Applications	19 March 2024
Rights trading ends at close of trading	22 March 2024
Securities quoted on a deferred settlement basis	25 March 2024
Last day to extend the Closing Date (before noon AEDT)	26 March 2024
Closing Date as at 5.00pm	2 April 2024
Announcement of results of the Entitlement Offer	5 April 2024
Issue of New Shares and New Options and lodgement of Appendix 2A with ASX applying for quotation of New Shares	8 April 2024
Quotation of New Shares issued under the Offer	9 April 2024
Issue of remaining Additional New Shares under Shortfall Offer (if any)	By no later than 3 months after the Closing Date

*Dates – other than the date of the Prospectus and the Prospectus Lodgement Date with ASIC and ASX – are indicative only. The Directors may decide to extend the Closing Date of the Entitlement Offer by notifying ASX – a minimum of three business days – before the Closing Date. Subsequently, the date that the Securities are expected to commence trading may vary.



Actions required by Eligible Shareholders

There are a number of actions Eligible Shareholders may take:

You may take up all or some of your entitlement to subscribe for New Shares pursuant to your Entitlement. To take up all or some of your Entitlements you will need to ensure your application money for the Entitlements you wish to take up is received by Automic no later than 5:00pm (WST) on Tuesday 2 April 2024, by making a payment by BPAY or EFT in accordance with the instructions on your Application Form.

If you have taken up all of your Entitlement, you may apply for additional New Shares via the Shortfall Offer.

You may seek to sell all or some of your Entitlements on ASX. You can seek to sell your Entitlements on ASX from 15 March 2024 until the close of market on 22 March 2024. To sell any of your Entitlements you need to contact your broker as soon as possible.

You may do nothing. If you choose to do nothing with your Entitlements, while you will continue to hold the same number of shares, your interest in the Company will be diluted and you will receive no value for your Entitlements.

Queries

If you have any questions about the Entitlement Offer, please contact:

Mark Leong

Executive Chairman

Osteopore Limited

E: mark_leong@osteopore.com

Kellie Davis

Company Secretary

Osteopore Limited

+61 2 8072 1400

E: kellie.davis@automicgroup.com.au

T:

For any other registry related matters, contact the Company's share registrar, Automic Group as follows:

Email: hello@automicgroup.com.au

Address: 126 Phillip Street, Sydney NSW 2000

Phone: 1300 288 664 (within Australia), or +61 2 9698 5414 (international) between 8:30am and 7:00pm (AEST) Monday to Friday.

ENDS



This announcement dated 19 March 2024 has been authorised for release to the ASX by the Board of Osteopore Limited.

About Osteopore Limited

Osteopore Limited is a Singapore-founded regenerative medicine company and a global leader in 3D-printed biomimetic and bioresorbable implants. The Company seeks to commercialise products that stimulate natural bone healing across multiple segments.

Osteopore creates patented scaffolds using 3D-printed biomimetic and bioresorbable materials to guide and nurture bone-forming cells.

Through our proprietary manufacturing process – which uses a naturally dissolving polymer – our patented scaffolds enable bone tissue growth, significantly reducing the post-surgery complications commonly associated with permanent bone implants.

Forward-Looking Statements

Statements contained in this release, particularly those regarding possible or assumed future performance, revenue, costs, dividends, production levels or rates, prices, or potential growth of Osteopore Limited, are or may be, forward-looking statements.

Such statements relate to future events and expectations and, as such, involve known and unknown risks and uncertainties. Depending on several factors, actual results may differ materially from those expressed or implied by these forward-looking statements.

